• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Global Equity

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
By ALEX FREW MCMILLAN
Jun 07, 2019 | 12:00 PM EDT
Stocks quotes in this article: SNY, LLY, BMY, SFOSF, GSK, NVS, SHPMY

The scandal over the biggest-known bribe to get your kid into college appears to have metastasized into a broad-based investigation of the Chinese pharmaceutical industry. Three multinationals are affected as the Chinese authorities search for dirt on kickbacks over drug sales.

The chairman of Chinese traditional medicine maker Shandong Buchang Pharmaceutical SH:603858, Zhao Tao, allegedly paid US$6.5 million to get his daughter, Molly Zhao, into Stanford University. While those revelations came to light amid a college-admissions scandal surrounding college "consultant" Rick Singer, Chinese regulators have now said they are launching a nationwide audit of drug companies in China.

In all, 77 drug makers are now having their financial statements poured over by China's National Healthcare Security Administration and the Ministry of Finance. The authorities this week said they would investigate rebates for sales expenses at the companies, which they say were selected at random.

The Chinese arms of Sanofi (SNY) Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) are on the list of 77 companies. So too is Buchang Pharmaceutical, which has seen its share price fall 25.1% since April 30 amid the college-admissions scandal.

The list of 77 also includes several other drug companies listed in Hong Kong and easily accessible to overseas investors. Shanghai Fosun Pharmaceutical HK:2196, (SFOSF) a unit of one of China's largest conglomerates, is also under audit.

The brokerage firm Nomura ties the investigation to public concerns about whether drug companies have been mis-reporting expenses for non-operational purposes.

"This doubt mainly arises from news reports regarding the Buchang Pharma scandal," Nomura China pharmaceutical analyst Stella Xing says in a report.

You don't always get the full explanation behind official action in China. Policy is often set unofficially, with companies finding out through hit and miss what they can do. Crackdowns can happen with no public announcement they are under way.

So, it may be that Chinese officials have moved after the great attention paid to the Stanford scandal. That's even though Zhao, the drug company chairman, issued a statement that any issues surrounding his daughter's university admission were a private matter.

"I'm the actual controller of Buchang Pharma, and I hereby state that my daughter studying in the United States is only a private action of my family, and the funding has no relation with Buchang Pharma," he said, according to a translation from the Epoch Times newspaper.

Zhao is worth US$4.6 billion, according to the 2018 Hurun Rich List of the richest people in China. He was photographed separately with both Chinese President Xi Jinping and with U.S. President Donald Trump in 2017, the year his daughter started at Stanford. That may not matter much to Trump but does not look good in Communist China under Xi's harsh crackdown on the "tigers and flies" among Chinese officialdom who engage in corruption.

Buchang Pharma, founded by Zhao's father, Zhao Buchang, has a checkered history when it comes to bribery. Zheng Xiaoyou, the former director of China's Food and Drug Administration, was executed in July 2007 after confessing to receiving bribes from eight drug companies, including Buchang Pharma. The Epoch Times has also uncovered at least five instances between 2015 and 2018 when it says sales representatives of Buchang Pharma bribed doctors or hospital presidents to sell its medicines.

There are other explanations for the crackdown on drugmakers, which should also concern investors.

Another maker of traditional Chinese medicines, Kangmei Pharmaceutical SH:600518, has also been probed directly by regulators recently. It said in April that it had overstated its cash holdings by as much as 29.9 billion yuan (US$4.3 billion).

China's stock watchdog, the China Securities Regulatory Commission, said Kangmei inflated cash deposits and income in its financial reports. The CSRC also said the company used related parties to manipulate the trading of its own shares.

In 2014, China fined GlaxoSmithKline (GSK) a record 3 billion yuan (US$489 million at the time) for bribing doctors to use its drugs. That caused great handwringing among overseas drug companies doing business in China. Some doctors say "gray revenues" of under-the-table payments are commonplace.

Novartis (NVS) paid a US$25 million fine to the U.S. government in 2016 to settle Foreign Corrupt Practices Act charges that its China-based subsidiaries paid to get their drugs prescribed.

China is also on a long-term push to drive down the cost of generic drugs. Nomura says the main outcome of the new investigation into the 77 companies may be that authorities will make use of the findings to push for further reductions in prices.

China's State Council issued a policy document outlining the path of health-care reform on June 4. It stated that the government would push through a second round of Group Purchase Organization price cuts by September.

That would put further pressure on margins for the makers of generic drugs. Investors should therefore be wary of those shares.

The other Hong Kong-listed companies on the investigation list are Hansoh Pharmaceutical Group HK:3692, the CSPC Zhongnuo Pharmaceutical subsidiary of CSPC HK:1093, Shanghai Pharmaceuticals Holding HK:2607 (SHPMY) , and a subsidiary of Sinopharm Holding HK:1099.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, McMillan had no positions in any securities mentioned.

TAGS: Investing | Pharmaceuticals | China | Global Equity

More from Global Equity

Naspers to Unlock Its Own Value By Selling Down $129B Tencent Stake

Alex Frew McMillan
Jun 29, 2022 6:32 AM EDT

Naspers and its investment-holding company Prosus will sell down their Tencent stake and buy their own shares, with both companies trading at big discounts to NAV.

India's Equity Market Sees Foreign Investors Sell at Record Rate

Alex Frew McMillan
Jun 27, 2022 8:00 AM EDT

After two years of strong buying, international investors are now dumping Indian stocks as they look to capture gains.

Chinese Tech Company Ximalaya Pulls Planned IPO Yet Again

Alex Frew McMillan
Jun 24, 2022 6:30 AM EDT

Poor market conditions and the uncertain status of Chinese tech listings cause the podcast market leader to put off its Hong Kong IPO.

Why It Costs $1B Per Year to Go Up Against Indonesia's GoTo Group

Alex Frew McMillan
Jun 22, 2022 6:30 AM EDT

It's not often you find a tech stock with defensive characteristics and a strong upside, but GoTo offers both.

Why Exporters in Japan, Domestic Plays in China Offer Protection

Alex Frew McMillan
Jun 17, 2022 8:01 AM EDT

Chinese stock markets have offered surprising strength while a weak yen will boost profits of Japanese firms that reap most of their sales overseas.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login